Nektar Iherapeutics news from FierceBiotech
NewsC&L: Somnus names executive team
Gary Cupit, PharmD, has been named CEO of Somnus Therapeutics. The rest of the executive team: Mary Osbakken, MD, PhD, chief medical officer; Christine Blumhardt, PharmD, chief regulatory officer; Read more...
A deluge of pre-ASCO data hits the market
As we mentioned earlier this week, data from almost 5,000 clinical studies was released last night in preparation for next week's ASCO meeting. And some of the most interesting data won't be released Read more...
Inhaled insulin lung cancer warning riles investors
The inhaled insulin field got blitzed again today after Nektar Therapeutics and Pfizer reported an increased number of Read more...
ALSO NOTED: Osiris inks $224M contract; Baxter and Nektar to collaborate;and much more...
> Osiris Therapeutics has inked a deal with the U.S. Defense Department to supply a potential $224 million worth of Prochymal for use in treating military personnel exposed to radiation. Read more...
ALSO NOTED: FDA says no to Indevus; Nektar gets sweetened deal with Baxter; Akela pulls public offering; and much more...
> Indevus Pharmaceuticals says that the FDA has turned thumbs down on its new therapy for bladder cancer, a move that trimmed its stock value. Valstar was pulled from the market five years ago Read more...
C&L: Somaxon names interim CEO
Somaxon Pharmaceuticals' current non-executive chairman of the board, David F. Hale, has been appointed executive chairman and will become interim CEO effective January 1, 2008. Kenneth M. Cohen has Read more...
Pfizer gives Nektar $135M for Exubera settlement
Nektar Therapeutics got a consolation prize of $135 million from Pfizer--and a fresh shot at signing a new partner--to calm any upset feelings about Read more...
Pearl Therapeutics finds $15.5M in first VC round
Upstart Pearl Therapeutics, which is developing therapies for respiratory disorders, has raised $15.5 million in its first round. The Redwood City, CA-based biotech's round was co-led by New Leaf Read more...
C&L: Worland tapped for Anadys post
Steve Worland has been promoted to the position of president and CEO of Anadys Pharmaceuticals. Depomed Chairman, President and CEO John Fara is retiring. Executive Vice President and COO Carl Read more...
DEALS: Pfizer, Icagen ink development pact
Pfizer, Icagen ink development pact DEALSWHOWITHWHATSCOOPPfizerIcagenDevelopment pactIcagen stands to pocket up Read more...
| Press ReleasesPRESS RELEASE: Pfizer and Nektar Reach Agreement on Exubera Pfizer and Nektar Reach Agreement on Exubera NEW YORK & SAN CARLOS, Calif. -- Pfizer and Nektar Therapeutics announced today that the two companies have resolved all outstanding contractual Read more... |
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends